\begin{itemize}
    \item validation of testing should be part of the state review,
    \item the state notify the agency should it choose to use this flexibility in oversight to expedite COVID-19 test development,
    \item clinical labs confirm the first five negative and positive test results against an EUA-authorized assay while awaiting FDA determination for EUA request.\cite{FDA20200306}
\end{itemize}